Detalhe da pesquisa
1.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
N Engl J Med
; 390(15): 1359-1371, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38631003
2.
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Lancet
; 402(10407): 1043-1051, 2023 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37524096
3.
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Oncologist
; 29(2): 142-150, 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589219
4.
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
N Engl J Med
; 385(8): 683-694, 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407342
5.
Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study.
BJU Int
; 133(2): 169-178, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589200
6.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
J Natl Compr Canc Netw
; 22(1): 4-16, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394781
7.
Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805.
J Natl Compr Canc Netw
; 21(7): 725-731.e1, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37433436
8.
Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs.
J Natl Compr Canc Netw
; 21(10): 1039-1049.e10, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37856199
9.
Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare datac.
Int J Urol
; 30(3): 272-279, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36788716
10.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(9): 1133-1144, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36055304
11.
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Lancet
; 397(10275): 695-703, 2021 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33592176
12.
ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study.
Oncologist
; 27(6): 453-461, 2022 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35373299
13.
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.
BJU Int
; 129(6): 718-722, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480522
14.
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(1): 71-90, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34991070
15.
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
J Urol
; 203(4): 684-689, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31596672
16.
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
J Natl Compr Canc Netw
; 18(9): 1160-1170, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32886895
17.
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Lancet Oncol
; 20(4): 581-590, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30827746
18.
Association between age and sex and mortality after adjuvant therapy for renal cancer.
Cancer
; 125(10): 1637-1644, 2019 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30620389
19.
Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.
J Urol
; 201(1): 62-68, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30130544
20.
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.
J Natl Compr Canc Netw
; 17(11): 1278-1285, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31693980